{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:17:02Z","timestamp":1792279022435,"version":"4.4.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Doxorubicin is a widely used anticancer drug whose efficacy is limited due to its cardiotoxicity. There is no ideal cardioprotection available against doxorubicin-induced cardiotoxicity. This study aimed to investigate the anticipated cardioprotective potential of metformin and dapagliflozin against doxorubicin-induced acute\u00a0cardiotoxicity in Wistar rats. At the beginning of the experiment, cardiac screening of experimental animals was done by recording an electrocardiogram (ECG) before allocating them into the groups. Thereafter, a total of thirty healthy adult Wistar rats (150\u2013200\u00a0g) were randomly divided into five groups (<jats:italic>n<\/jats:italic>\u2009=\u20096) and treated for eight days as follows: group I (normal control), group II (doxorubicin control), group III (metformin 250\u00a0mg\/kg\/day), group IV (metformin 180\u00a0mg\/kg\/day), and group V (dapagliflozin 0.9\u00a0mg\/kg\/day). On the 7th day of the treatment phase, doxorubicin 20\u00a0mg\/kg was administered intraperitoneal to groups II, III, IV, and V. On the 9th day (immediately after 48\u00a0h of doxorubicin administration), blood was collected from anesthetized animals for glucose, lipid profile, CK-MB &amp; AST estimation, and ECG was recorded. Later, animals were sacrificed, and the heart was dissected for histopathological examination. We found that compared to normal control rats, CK-MB, AST, and glucose were significantly increased in doxorubicin control rats. There was a significant reversal of doxorubicin-induced hyperglycemia in the rats treated with metformin 250\u00a0mg\/kg compared to doxorubicin control rats. Both metformin (180\u00a0mg\/kg and 250\u00a0mg\/kg) and dapagliflozin (0.9\u00a0mg\/kg) significantly altered doxorubicin-induced ECG changes and reduced the levels of cardiac injury biomarkers CK-MB and AST compared to doxorubicin control rats. Metformin and dapagliflozin protected the cellular architecture of the myocardium from doxorubicin-induced myocardial injury. Current study revealed that both metformin and dapagliflozin at the FDA-recommended antidiabetic doses mitigated doxorubicin-induced acute\u00a0cardiotoxicity in Wistar rats. The obtained data have opened the perspective to perform chronic studies and then to clinical studies to precisely consider metformin and dapagliflozin as potential chemoprotection in the combination of chemotherapy with doxorubicin to limit its cardiotoxicity, especially in patients with comorbid conditions like type II diabetes mellitus.\n<\/jats:p>","DOI":"10.1007\/s12012-023-09784-8","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T21:13:36Z","timestamp":1677014016000},"page":"107-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Metformin and Dapagliflozin Attenuate Doxorubicin-Induced Acute\u00a0Cardiotoxicity in Wistar Rats: An Electrocardiographic, Biochemical, and Histopathological Approach"],"prefix":"10.1007","volume":"23","author":[{"given":"Shakta Mani","family":"Satyam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxminarayana Kurady","family":"Bairy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakashchandra","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sainath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Bharati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akheruz Zaman","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Ashwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"9784_CR1","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s10741-020-09968-2","volume":"26","author":"Y Saleh","year":"2021","unstructured":"Saleh, Y., Abdelkarim, O., Herzallah, K., & Abela, G. S. (2021). Anthracycline-induced cardiotoxicity: Mechanisms of action, incidence, risk factors, prevention, and treatment. Heart Failure Reviews, 26, 1159\u20131173. https:\/\/doi.org\/10.1007\/s10741-020-09968-2","journal-title":"Heart Failure Reviews"},{"key":"9784_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10549-020-05703-5","volume":"182","author":"H Cho","year":"2020","unstructured":"Cho, H., Lee, S., Sim, S. H., Park, I. H., Lee, K. S., Kwak, M. H., & Kim, H. J. (2020). Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients. Breast Cancer Research and Treatment, 182, 333\u2013343. https:\/\/doi.org\/10.1007\/s10549-020-05703-5","journal-title":"Breast Cancer Research and Treatment"},{"key":"9784_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1152\/ajpheart.01023.2001","volume":"283","author":"X Liu","year":"2002","unstructured":"Liu, X., Chen, Z., Chua, C. C., Ma, Y. S., Youngberg, G. A., Hamdy, R., & Chua, B. H. (2002). Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. American Journal of Physiology. Heart and Circulatory Physiology, 283, 254\u2013263. https:\/\/doi.org\/10.1152\/ajpheart.01023.2001","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"9784_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4149\/BLL_2019_045","volume":"120","author":"H Aygun","year":"2019","unstructured":"Aygun, H., & Gul, S. S. (2019). Cardioprotective effect of melatonin and agomelatine on doxorubicin-induced cardiotoxicity in a rat model: An electrocardiographic, scintigraphic and biochemical study. Bratislavske Lekarske Listy, 120, 249\u2013255. https:\/\/doi.org\/10.4149\/BLL_2019_045","journal-title":"Bratislavske Lekarske Listy"},{"key":"9784_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijcard.2006.05.005","volume":"117","author":"D Outomuro","year":"2007","unstructured":"Outomuro, D., Grana, D. R., Azzato, F., & Milei, J. (2007). Adriamycin-induced myocardial toxicity: New solutions for an old problem. International Journal of Cardiology, 117, 6\u201315. https:\/\/doi.org\/10.1016\/j.ijcard.2006.05.005","journal-title":"International Journal of Cardiology"},{"key":"9784_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/0973-1482.131370","volume":"10","author":"R Indu","year":"2014","unstructured":"Indu, R., Azhar, T. S., Nair, A., & Nair, C. K. (2014). Amelioration of doxorubicin-induced cardio-and hepatotoxicity by carotenoids. Journal of Cancer Research and Therapeutics, 10, 62\u201367. https:\/\/doi.org\/10.4103\/0973-1482.131370","journal-title":"Journal of Cancer Research and Therapeutics"},{"key":"9784_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/0002-9343(78)90802-1","volume":"65","author":"MR Bristow","year":"1978","unstructured":"Bristow, M. R., Thompson, P. D., Martin, R. P., Mason, J. W., Billingham, M. E., & Harrison, D. C. (1978). Early anthracycline cardiotoxicity. American Journal of Medicine, 65, 823\u2013832. https:\/\/doi.org\/10.1016\/0002-9343(78)90802-1","journal-title":"American Journal of Medicine"},{"key":"9784_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017). Anthracycline chemotherapy, and cardiotoxicity. Cardiovascular Drugs and Therapy, 31, 63\u201375. https:\/\/doi.org\/10.1007\/s10557-016-6711-0","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"9784_CR9","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer, 97, 2869\u20132879. https:\/\/doi.org\/10.1002\/cncr.11407","journal-title":"Cancer"},{"key":"9784_CR10","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., & Fiorentini, C. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation, 131, 1981\u20131988. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013777","journal-title":"Circulation"},{"key":"9784_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jtemb.2018.01.016","volume":"47","author":"S Sangomla","year":"2018","unstructured":"Sangomla, S., Saifi, M. A., Khurana, A., & Godugu, C. (2018). Nanoceria ameliorates doxorubicin-induced cardiotoxicity: Possible mitigation via reduction of oxidative stress and inflammation. Journal of Trace Elements in Medicine and Biology, 47, 53\u201362. https:\/\/doi.org\/10.1016\/j.jtemb.2018.01.016","journal-title":"Journal of Trace Elements in Medicine and Biology"},{"key":"9784_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109547","author":"W Qi","year":"2020","unstructured":"Qi, W., Boliang, W., Xiaoxi, T., Guoqiang, F., Jianbo, X., & Gang, W. (2020). Cardamonin protects against doxorubicin-induced cardiotoxicity in mice by restraining oxidative stress and inflammation associated with Nrf2 signaling. Biomedicine & Pharmacotherapy. https:\/\/doi.org\/10.1016\/j.biopha.2019.109547","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"9784_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00280-017-3413-7","volume":"80","author":"MM Abdel-Daim","year":"2017","unstructured":"Abdel-Daim, M. M., Khalifa, H. A., & Ahmed, A. A. (2017). Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation, and apoptosis. Cancer Chemotherapy and Pharmacology, 80, 745\u2013753. https:\/\/doi.org\/10.1007\/s00280-017-3413-7","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"7","key":"9784_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/2FFPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011). Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenetics and Genomics, 21(7), 440. https:\/\/doi.org\/10.1097\/2FFPC.0b013e32833ffb56","journal-title":"Pharmacogenetics and Genomics"},{"key":"9784_CR15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.bbamcr.2011.03.002","volume":"1813","author":"AV Kuznetsov","year":"2011","unstructured":"Kuznetsov, A. V., Margreiter, R., Amberger, A., Saks, V., & Grimm, M. (2011). Changes in mitochondrial redox state, membrane potential, and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. Biochimica et Biophysica Acta, 1813, 1144\u20131152. https:\/\/doi.org\/10.1016\/j.bbamcr.2011.03.002","journal-title":"Biochimica et Biophysica Acta"},{"key":"9784_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/a:1007094214460","volume":"207","author":"P Singal","year":"2000","unstructured":"Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000). Adriamycin-induced heart failure: Mechanisms and modulation. Molecular and Cellular Biochemistry, 207, 77\u201386. https:\/\/doi.org\/10.1023\/a:1007094214460","journal-title":"Molecular and Cellular Biochemistry"},{"key":"9784_CR17","doi-asserted-by":"publisher","unstructured":"Dos-Santos DS, dos Santos Goldenberg RC (2018) Doxorubicin-induced cardiotoxicity from mechanisms to the development of efficient therapy. In: Cardiotoxicity, Intechopen, UK, pp 3\u201324. https:\/\/doi.org\/10.5772\/intechopen.79588","DOI":"10.5772\/intechopen.79588"},{"key":"9784_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s005200100293","volume":"10","author":"GR Morrow","year":"2002","unstructured":"Morrow, G. R., Andrews, P. L., Hickok, J. T., Roscoe, J. A., & Matteson, S. (2002). Fatigue associated with cancer and its treatment. Supportive Care in Cancer, 10, 389\u2013398. https:\/\/doi.org\/10.1007\/s005200100293","journal-title":"Supportive Care in Cancer"},{"key":"9784_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/mus.20467","volume":"33","author":"M Gorselink","year":"2006","unstructured":"Gorselink, M., Vaessen, S. F., van der Flier, L. G., Leenders, I., Kegler, D., Caldenhoven, E., van der Beek, E., & van Helvoort, A. (2006). Mass-dependent decline of skeletal muscle function in cancer cachexia. Muscle and Nerve, 33, 691\u2013693. https:\/\/doi.org\/10.1002\/mus.20467","journal-title":"Muscle and Nerve"},{"key":"9784_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104888","author":"LC Kobashigawa","year":"2014","unstructured":"Kobashigawa, L. C., Xu, Y. C., Padbury, J. F., Tseng, Y. T., & Yano, N. (2014). Metformin protects cardiomyocytes from doxorubicin-induced cytotoxicity through an AMP-activated protein kinase-dependent signaling pathway: An in vitro study. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0104888","journal-title":"PLoS ONE"},{"issue":"10","key":"9784_CR21","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1073\/pnas.85.10.3585","volume":"85","author":"RD Olson","year":"1988","unstructured":"Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K., & Boucek, R. J., Jr. (1988). Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proceedings of the National Academy of Sciences, 85(10), 3585\u20133589. https:\/\/doi.org\/10.1073\/pnas.85.10.3585","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"9784_CR22","first-page":"396","volume":"294","author":"DM Weinstein","year":"2000","unstructured":"Weinstein, D. M., Mihm, M. J., & Bauer, J. A. (2000). Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. Journal of Pharmacology and Experimental Therapeutics, 294(1), 396\u2013401.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"24","key":"9784_CR23","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","volume":"112","author":"L Wojnowski","year":"2005","unstructured":"Wojnowski, L., Kulle, B., Schirmer, M., Schl\u00fcter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeb\u00f6ller, H., Toliat, M. R., Suk, E. K., & Tzvetkov, M. (2005). NAD (P) H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation, 112(24), 3754\u20133762. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.576850","journal-title":"Circulation"},{"issue":"3B","key":"9784_CR24","first-page":"2445","volume":"23","author":"ME Clementi","year":"2003","unstructured":"Clementi, M. E., Giardina, B., Di Stasio, E., Mordente, A., & Misiti, F. (2003). Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Research, 23(3B), 2445\u20132450.","journal-title":"Anticancer Research"},{"issue":"4","key":"9784_CR25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/bf00254234","volume":"22","author":"BJ Cusack","year":"1988","unstructured":"Cusack, B. J., Tesnohlidek, D. A., Loseke, V. L., Vestal, R. E., Brenner, D. E., & Olson, R. D. (1988). Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemotherapy and Pharmacology, 22(4), 294\u2013298. https:\/\/doi.org\/10.1007\/bf00254234","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"2","key":"9784_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12012-007-0013-5","volume":"7","author":"L Gianni","year":"2007","unstructured":"Gianni, L., Salvatorelli, E., & Minotti, G. (2007). Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes. Cardiovascular Toxicology, 7(2), 67\u201371. https:\/\/doi.org\/10.1007\/s12012-007-0013-5","journal-title":"Cardiovascular Toxicology"},{"issue":"10","key":"9784_CR27","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2174\/138920112802273245","volume":"13","author":"JH Doroshow","year":"2012","unstructured":"Doroshow, J. H. (2012). Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Current Pharmaceutical Biotechnology., 13(10), 1949\u20131956. https:\/\/doi.org\/10.2174\/138920112802273245","journal-title":"Current Pharmaceutical Biotechnology."},{"issue":"25","key":"9784_CR28","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2217\/fon-2018-0210","volume":"14","author":"P Reichardt","year":"2018","unstructured":"Reichardt, P., Tabone, M. D., Mora, J., Morland, B., & Jones, R. L. (2018). Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: Re-evaluating the European labeling. Future Oncology, 14(25), 2663\u20132676. https:\/\/doi.org\/10.2217\/fon-2018-0210","journal-title":"Future Oncology"},{"key":"9784_CR29","unstructured":"Eneh, C., & Lekkala, M. R. (2022). Dexrazoxane. In StatPearls 2022. StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560559\/"},{"key":"9784_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8237264","volume":"2016","author":"VH Oidor-Chan","year":"2016","unstructured":"Oidor-Chan, V. H., Hong, E., P\u00e9rez-Severiano, F., Montes, S., Torres-Narv\u00e1ez, J. C., del Valle-Mondrag\u00f3n, L., Pastel\u00edn-Hern\u00e1ndez, G., & S\u00e1nchez-Mendoza, A. (2016). Fenofibrate plus metformin produces cardioprotection in a type 2 diabetes and acute myocardial infarction model. PPAR Research, 2016, 1\u201314. https:\/\/doi.org\/10.1155\/2016\/8237264","journal-title":"PPAR Research"},{"key":"9784_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1055\/s-2002-26705","volume":"34","author":"RJ Legtenberg","year":"2002","unstructured":"Legtenberg, R. J., Houston, R. J., Oeseburg, B., & Smits, P. (2002). Metformin improves cardiac functional recovery after ischemia in rats. Hormone and Metabolic Research, 34, 182\u2013185. https:\/\/doi.org\/10.1055\/s-2002-26705","journal-title":"Hormone and Metabolic Research"},{"key":"9784_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1742-7843.2008.00234.x","volume":"103","author":"L Solskov","year":"2008","unstructured":"Solskov, L., L\u00f8fgren, B., Kristiansen, S. B., Jessen, N., Pold, R., Nielsen, T. T., B\u00f8tker, H. E., Schmitz, O., & Lund, S. (2008). Metformin induces cardioprotection against ischemia\/reperfusion injury in the rat heart 24 hours after administration. Basic & Clinical Pharmacology & Toxicology, 103, 82\u201387. https:\/\/doi.org\/10.1111\/j.1742-7843.2008.00234.x","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"9784_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/907496","volume":"2011","author":"E Kravchuk","year":"2011","unstructured":"Kravchuk, E., Grineva, E., Bairamov, A., Galagudza, M., & Vlasov, T. (2011). The effect of metformin on the myocardial tolerance to ischemia-reperfusion injury in the rat model of diabetes mellitus type II. Experimental Diabetes Research, 2011, 1\u20135. https:\/\/doi.org\/10.1155\/2011\/907496","journal-title":"Experimental Diabetes Research"},{"key":"9784_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.taap.2018.10.004","volume":"362","author":"VR Amara","year":"2019","unstructured":"Amara, V. R., Surapaneni, S. K., & Tikoo, K. (2019). Metformin attenuates cardiovascular and renal injury in uninephrectomized rats on DOCA-salt: Involvement of AMPK and miRNAs in cardioprotection. Toxicology and Applied Pharmacology, 362, 95\u2013104. https:\/\/doi.org\/10.1016\/j.taap.2018.10.004","journal-title":"Toxicology and Applied Pharmacology"},{"key":"9784_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1755-5922.12279","volume":"35","author":"R Ramachandran","year":"2017","unstructured":"Ramachandran, R., & Saraswathi, M. (2017). Postconditioning with metformin attenuates apoptotic events in cardiomyoblasts associated with ischemic reperfusion injury. Cardiovascular Therapeutics, 35, 1\u201310. https:\/\/doi.org\/10.1111\/1755-5922.12279","journal-title":"Cardiovascular Therapeutics"},{"key":"9784_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.metabol.2003.07.020","volume":"53","author":"F Abbasi","year":"2004","unstructured":"Abbasi, F., Chu, J. W., McLaughlin, T., Lamendola, C., Leary, E. T., & Reaven, G. M. (2004). Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism, 53, 159\u2013164. https:\/\/doi.org\/10.1016\/j.metabol.2003.07.020","journal-title":"Metabolism"},{"key":"9784_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10557-012-6425-x","volume":"27","author":"HJ Whittington","year":"2013","unstructured":"Whittington, H. J., Hall, A. R., McLaughlin, C. P., Hausenloy, D. J., Yellon, D. M., & Mocanu, M. M. (2013). Chronic metformin-associated cardioprotection against infarction: Not just a glucose-lowering phenomenon. Cardiovascular Drugs and Therapy, 27, 5\u201316. https:\/\/doi.org\/10.1007\/s10557-012-6425-x","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"9784_CR38","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1152\/ajpheart.00319.2008","volume":"295","author":"CX Fang","year":"2008","unstructured":"Fang, C. X., Dong, F., Thomas, D. P., Ma, H., He, L., & Ren, J. (2008). Hypertrophic cardiomyopathy in high-fat diet-induced obesity: Role of suppression of forkhead transcription factor and atrophy gene transcription. American Journal of Physiology Heart and Circulatory Physiology, 295, 1206\u20131215. https:\/\/doi.org\/10.1152\/ajpheart.00319.2008","journal-title":"American Journal of Physiology Heart and Circulatory Physiology"},{"key":"9784_CR39","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00204-020-02951-8","volume":"95","author":"WT Chang","year":"2021","unstructured":"Chang, W. T., Lin, Y. W., Ho, C. H., Chen, Z. C., Liu, P. Y., & Shih, J. Y. (2021). Dapagliflozin protects doxorubicin-induced cardiotoxicity in breast cancer patients with diabetes via suppressing ER stress. Archives of Toxicology, 95, 659\u2013671. https:\/\/doi.org\/10.1007\/s00204-020-02951-8","journal-title":"Archives of Toxicology"},{"key":"9784_CR40","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/ATVBAHA.119.310961","volume":"39","author":"AM Schmidt","year":"2019","unstructured":"Schmidt, A. M. (2019). Diabetes mellitus and cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 39, 558\u2013568. https:\/\/doi.org\/10.1161\/ATVBAHA.119.310961","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"9784_CR41","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1177\/0960327115608246","volume":"35","author":"KK Vattam","year":"2016","unstructured":"Vattam, K. K., Raghavendran, H. R., Murali, M. R., Savatey, H., & Kamarul, T. (2016). Co-administration of alloxan and nicotinamide in rats produces biochemical changes in blood and pathological alterations comparable to the changes in type II diabetes mellitus. Human and Experimental Toxicology, 35, 893\u2013901. https:\/\/doi.org\/10.1177\/0960327115608246","journal-title":"Human and Experimental Toxicology"},{"key":"9784_CR42","doi-asserted-by":"publisher","unstructured":"Paget, G. E., & Barnes, J. M. (1964). Toxicity tests in the evaluation of drug activities. In: Laurence, D. R., & Bacharach, A. L. (Eds.) Pharmacometrics (1st edn). Massachusetts, pp 135\u2013166. https:\/\/doi.org\/10.1016\/B978-1-4832-2845-7.50012-8","DOI":"10.1016\/B978-1-4832-2845-7.50012-8"},{"key":"9784_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6694340","author":"AZ Ahmed","year":"2021","unstructured":"Ahmed, A. Z., Satyam, S. M., Shetty, P., & D\u2019Souza, M. R. (2021). Methyl gallate attenuates doxorubicin-induced cardiotoxicity in rats by suppressing oxidative stress. Scientifica. https:\/\/doi.org\/10.1155\/2021\/6694340","journal-title":"Scientifica"},{"key":"9784_CR44","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1007\/s13197-014-1305-y","volume":"52","author":"SM Satyam","year":"2015","unstructured":"Satyam, S. M., Bairy, L. K., Pirasanthan, R., & Vaishnav, R. L. (2015). Grape seed extract and Zinc containing nutritional food supplement delays onset and progression of Streptozocin-induced diabetic cataract in Wistar rats. Journal of Food Science and Technology, 52, 2824\u20132832. https:\/\/doi.org\/10.1007\/s13197-014-1305-y","journal-title":"Journal of Food Science and Technology"},{"key":"9784_CR45","doi-asserted-by":"publisher","first-page":"65802","DOI":"10.1007\/s11356-021-15409-w","volume":"46","author":"SA Abdulkareem Aljumaily","year":"2021","unstructured":"Abdulkareem Aljumaily, S. A., Demir, M., Elbe, H., Yigitturk, G., Bicer, Y., & Altinoz, E. (2021). Antioxidant, anti-inflammatory, and anti-apoptotic effects of crocin against doxorubicin-induced myocardial toxicity in rats. Environmental Science and Pollution Research., 46, 65802\u201365813. https:\/\/doi.org\/10.1007\/s11356-021-15409-w","journal-title":"Environmental Science and Pollution Research."},{"key":"9784_CR46","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/s0005-2736(01)00371-6","volume":"1514","author":"MA Parker","year":"2001","unstructured":"Parker, M. A., King, V., & Howard, K. P. (2001). Nuclear magnetic resonance study of doxorubicin binding to cardiolipin containing magnetically oriented phospholipid bilayers. Biochimica et Biophysica Acta, 1514, 206\u2013216. https:\/\/doi.org\/10.1016\/s0005-2736(01)00371-6","journal-title":"Biochimica et Biophysica Acta"},{"key":"9784_CR47","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000265166","volume":"115","author":"K Chatterjee","year":"2010","unstructured":"Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010). Doxorubicin cardiomyopathy. Cardiology, 115, 155\u2013162. https:\/\/doi.org\/10.1159\/000265166","journal-title":"Cardiology"},{"key":"9784_CR48","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3109\/13880209.2012.729065","volume":"51","author":"ES Ammar","year":"2013","unstructured":"Ammar, E. S., Said, S. A., El-Damarawy, S. L., & Suddek, G. M. (2013). Cardioprotective effect of grape-seed proanthocyanidins on doxorubicin-induced cardiac toxicity in rats. Pharmaceutical Biology, 51, 339\u2013344. https:\/\/doi.org\/10.3109\/13880209.2012.729065","journal-title":"Pharmaceutical Biology"},{"key":"9784_CR49","doi-asserted-by":"publisher","first-page":"717","DOI":"10.33549\/physiolres.933270","volume":"65","author":"P Konopelski","year":"2016","unstructured":"Konopelski, P., & Ufnal, M. (2016). Electrocardiography in rats: a comparison to a human. Physiological Research, 65, 717\u2013725.","journal-title":"Physiological Research"},{"key":"9784_CR50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/00005344-200407000-00017","volume":"44","author":"K Haugan","year":"2004","unstructured":"Haugan, K., Lam, H. R., Knudsen, C. B., & Petersen, J. S. (2004). Atrial fibrillation in rats induced by rapid transesophageal atrial pacing during brief episodes of asphyxia: A new in vivo model. Journal of Cardiovascular Pharmacology, 44, 125\u2013135. https:\/\/doi.org\/10.1097\/00005344-200407000-00017","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"9784_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pcad.2005.06.002","volume":"48","author":"S Nattel","year":"2005","unstructured":"Nattel, S., Shiroshita-Takeshita, A., Brundel, B. J., & Rivard, L. (2005). Mechanisms of atrial fibrillation: Lessons from animal models. Progress in Cardiovascular Diseases, 48, 9\u201328. https:\/\/doi.org\/10.1016\/j.pcad.2005.06.002","journal-title":"Progress in Cardiovascular Diseases"},{"key":"9784_CR52","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1161\/01.res.8.6.1200","volume":"8","author":"BF Hoffman","year":"1960","unstructured":"Hoffman, B. F., Cranefield, P. F., Stuckey, J. H., Bagdonas, A. A., & Piera, J. (1960). Electrical activity during the PR interval. Circulation Research, 8, 1200\u20131211. https:\/\/doi.org\/10.1161\/01.res.8.6.1200","journal-title":"Circulation Research"},{"key":"9784_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1152\/ajplegacy.1968.214.1.205","volume":"214","author":"WH Beinfield","year":"1968","unstructured":"Beinfield, W. H., & Lehr, D. A. (1968). PR interval of the rat electrocardiogram. American Journal of Physiology, 214, 205\u2013211. https:\/\/doi.org\/10.1152\/ajplegacy.1968.214.1.205","journal-title":"American Journal of Physiology"},{"key":"9784_CR54","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/toxsci\/kfp092","volume":"110","author":"MS Hazari","year":"2009","unstructured":"Hazari, M. S., Haykal-Coates, N., Winsett, D. W., Costa, D. L., & Farraj, A. K. (2009). Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin. Toxicological Sciences, 110, 224\u2013234. https:\/\/doi.org\/10.1093\/toxsci\/kfp092","journal-title":"Toxicological Sciences"},{"key":"9784_CR55","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.18203\/2319-2003.ijbcp20171656","volume":"6","author":"PM Emeka","year":"2017","unstructured":"Emeka, P. M., & Al-Ahmed, A. (2017). Effect of metformin on ECG, HR, and BP of rats administered with cardiotoxic agent doxorubicin. International Journal of Basic & Clinical Pharmacology, 6, 1054\u20131059.","journal-title":"International Journal of Basic & Clinical Pharmacology"},{"key":"9784_CR56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.tox.2007.09.026","volume":"243","author":"RB Kelishomi","year":"2008","unstructured":"Kelishomi, R. B., Ejtemaeemehr, S., Tavangar, S. M., Rahimian, R., Mobarakeh, J. I., & Dehpour, A. R. (2008). Morphine is protective against doxorubicin-induced cardiotoxicity in the rat. Toxicology, 243, 96\u2013104. https:\/\/doi.org\/10.1016\/j.tox.2007.09.026","journal-title":"Toxicology"},{"key":"9784_CR57","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jelectrocard.2008.06.021","volume":"41","author":"JE Madias","year":"2008","unstructured":"Madias, J. E. (2008). Low QRS voltage and its causes. Journal of Electrocardiology, 41, 498\u2013500. https:\/\/doi.org\/10.1016\/j.jelectrocard.2008.06.021","journal-title":"Journal of Electrocardiology"},{"key":"9784_CR58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.eupc.2004.12.012","volume":"7","author":"S Kilickap","year":"2005","unstructured":"Kilickap, S., Akgul, E., Aksoy, S., Aytemir, K., & Barista, I. (2005). Doxorubicin-induced second degree and complete atrioventricular block. Europace, 7, 227\u2013230. https:\/\/doi.org\/10.1016\/j.eupc.2004.12.012","journal-title":"Europace"},{"key":"9784_CR59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1152\/ajpheart.00818.2012","volume":"306","author":"A Chrastina","year":"2014","unstructured":"Chrastina, A., Pokreisz, P., & Schnitzer, J. E. (2014). Experimental model of transthoracic, vascular-targeted, photo dynamically induced myocardial infarction. American Journal of Physiology. Heart and Circulatory Physiology, 306, 270\u2013278. https:\/\/doi.org\/10.1152\/ajpheart.00818.2012","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"9784_CR60","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1161\/01.res.75.3.586","volume":"75","author":"ME Speechly-Dick","year":"1994","unstructured":"Speechly-Dick, M. E., Mocanu, M. M., & Yellon, D. M. (1994). Protein kinase C: Its role in ischemic preconditioning in the rat. Circulation Research, 75, 586\u2013590. https:\/\/doi.org\/10.1161\/01.res.75.3.586","journal-title":"Circulation Research"},{"key":"9784_CR61","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1161\/01.res.8.1.129","volume":"8","author":"MP Sambhi","year":"1960","unstructured":"Sambhi, M. P., & White, F. N. (1960). The electrocardiogram of the normal and hypertensive rat. Circulation Research, 8, 129\u2013134. https:\/\/doi.org\/10.1161\/01.res.8.1.129","journal-title":"Circulation Research"},{"key":"9784_CR62","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1021\/js980256r","volume":"88","author":"E Hanada","year":"1999","unstructured":"Hanada, E., Ohtani, H., Kotaki, H., Sawada, Y., Sato, H., & Iga, T. (1999). Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats. Journal of Pharmaceutical Sciences, 88, 234\u2013240. https:\/\/doi.org\/10.1021\/js980256r","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"9784_CR63","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden, D. M. (2004). Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350, 1013\u20131022. https:\/\/doi.org\/10.1056\/NEJMra032426","journal-title":"New England Journal of Medicine"},{"key":"9784_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.117.007724","volume":"6","author":"A Porta-Sanchez","year":"2017","unstructured":"Porta-Sanchez, A., Gilbert, C., Spears, D., Amir, E., Chan, J., Nanthakumar, K., & Thavendiranathan, P. (2017). Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: A systematic review. Journal of the American Heart Association, 6, 1\u201318. https:\/\/doi.org\/10.1161\/JAHA.117.007724","journal-title":"Journal of the American Heart Association"},{"key":"9784_CR65","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.egja.2013.08.003","volume":"30","author":"A Venugopal","year":"2014","unstructured":"Venugopal, A., Rajasree, O., & Koshy, R. C. (2014). Effect of anthracyclines and isoflurane on QTc interval. Egypt J Anaesth, 30, 83\u201387. https:\/\/doi.org\/10.1016\/j.egja.2013.08.003","journal-title":"Egypt J Anaesth"},{"key":"9784_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0002-9149(93)90035-b","volume":"72","author":"C Funck-Brentano","year":"1993","unstructured":"Funck-Brentano, C., & Jaillon, P. (1993). Rate-corrected QT interval: Techniques and limitations. American Journal of Cardiology, 72, 17\u201322. https:\/\/doi.org\/10.1016\/0002-9149(93)90035-b","journal-title":"American Journal of Cardiology"},{"key":"9784_CR67","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/0002-8703(85)90564-2","volume":"109","author":"S Ahnve","year":"1985","unstructured":"Ahnve, S. (1985). Correction of the QT interval for heart rate: A review of different formulas and the use of Bazett\u2019s formula in myocardial infarction. American Heart Journal, 109, 568\u2013574. https:\/\/doi.org\/10.1016\/0002-8703(85)90564-2","journal-title":"American Heart Journal"},{"key":"9784_CR68","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/s1734-1140(12)70945-3","volume":"64","author":"H Soraya","year":"2012","unstructured":"Soraya, H., Khorrami, A., Garjani, A., Maleki-Dizaji, N., & Garjani, A. (2012). Acute treatment with metformin improves cardiac function following isoproterenol-induced myocardial infarction in rats. Pharmacological Reports, 64, 1476\u20131484. https:\/\/doi.org\/10.1016\/s1734-1140(12)70945-3","journal-title":"Pharmacological Reports"},{"key":"9784_CR69","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1590\/s0066-782x2008000400004","volume":"90","author":"EC Costa","year":"2008","unstructured":"Costa, E. C., Gon\u00e7alves, A. A., Areas, M. A., & Morgabel, R. G. (2008). Effects of metformin on QT and QTc interval dispersion of diabetic rats. Arquivos Brasileiros de Cardiologia, 90, 232\u2013238. https:\/\/doi.org\/10.1590\/s0066-782x2008000400004","journal-title":"Arquivos Brasileiros de Cardiologia"},{"key":"9784_CR70","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13300-011-0003-2","volume":"2","author":"GF Carlson","year":"2011","unstructured":"Carlson, G. F., Tou, C. K., Parikh, S., Birmingham, B. K., & Butler, K. (2011). Evaluation of the effect of dapagliflozin on cardiac repolarization: A thorough QT\/QTc study. Diabetes Ther, 2, 123\u2013132. https:\/\/doi.org\/10.1007\/s13300-011-0003-2","journal-title":"Diabetes Ther"},{"key":"9784_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-020-01066-9","volume":"19","author":"S Lahnwong","year":"2020","unstructured":"Lahnwong, S., Palee, S., Apaijai, N., Sriwichaiin, S., Kerdphoo, S., Jaiwongkam, T., Chattipakorn, S. C., & Chattipakorn, N. (2020). Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury. Cardiovascular Diabetology, 19, 1\u20133. https:\/\/doi.org\/10.1186\/s12933-020-01066-9","journal-title":"Cardiovascular Diabetology"},{"key":"9784_CR72","doi-asserted-by":"publisher","first-page":"49","DOI":"10.7197\/cmj.879083","volume":"43","author":"O Akhan","year":"2021","unstructured":"Akhan, O., Sahin, E. \u015e, Ramazan, R. A., & Aktas, A. A. (2021). Comparison of the effects of SGLT 2 inhibitors and sulfonylurea on electrocardiographic parameters. Cumhuriyet Medical Journal, 43, 49\u201354. https:\/\/doi.org\/10.7197\/cmj.879083","journal-title":"Cumhuriyet Medical Journal"},{"key":"9784_CR73","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1172\/JCI66218","volume":"123","author":"LL Dugan","year":"2013","unstructured":"Dugan, L. L., You, Y. H., Ali, S. S., Diamond-Stanic, M., Miyamoto, S., DeCleves, A. E., Andreyev, A., Quach, T., Ly, S., Shekhtman, G., & Nguyen, W. (2013). AMPK dysregulation promotes the diabetes-related reduction of superoxide and mitochondrial function. The Journal of Clinical Investigation, 123, 4888\u20134899. https:\/\/doi.org\/10.1172\/JCI66218","journal-title":"The Journal of Clinical Investigation"},{"key":"9784_CR74","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/0971-6580.97218","volume":"19","author":"SL Shah","year":"2012","unstructured":"Shah, S. L., Mali, V. R., Zambare, G. N., & Bodhankar, S. L. (2012). Cardioprotective activity of methanol extract of the fruit of Trichosanthes cucumerina on doxorubicin-induced cardiotoxicity in Wistar rats. Toxicology International, 19, 167\u2013172. https:\/\/doi.org\/10.4103\/0971-6580.97218","journal-title":"Toxicology International"},{"key":"9784_CR75","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bcp.2015.02.006","volume":"95","author":"NM Saeed","year":"2015","unstructured":"Saeed, N. M., El-Naga, R. N., El-Bakly, W. M., Abdel-Rahman, H. M., El-Din, R. A. S., & El-Demerdash, E. (2015). Epigallocatechin-3-gallate pretreatment attenuates doxorubicin-induced cardiotoxicity in rats: A mechanistic study. Biochemical Pharmacology, 95, 145\u2013155. https:\/\/doi.org\/10.1016\/j.bcp.2015.02.006","journal-title":"Biochemical Pharmacology"},{"key":"9784_CR76","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1074\/jbc.M111.315812","volume":"287","author":"S Wang","year":"2012","unstructured":"Wang, S., Song, P., & Zou, M. H. (2012). Inhibition of AMP-activated protein kinase \u03b1 (AMPK\u03b1) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: Role of p53 and SIRT1. Journal of Biological Chemistry, 287, 8001\u20138012. https:\/\/doi.org\/10.1074\/jbc.M111.315812","journal-title":"Journal of Biological Chemistry"},{"key":"9784_CR77","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/01.RES.0000256090.42690.05","volume":"100","author":"MC Towler","year":"2007","unstructured":"Towler, M. C., & Hardie, D. G. (2007). AMP-activated protein kinase in metabolic control and insulin signaling. Circulation Research, 100, 328\u2013341. https:\/\/doi.org\/10.1161\/01.RES.0000256090.42690.05","journal-title":"Circulation Research"},{"key":"9784_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-018-0745-5","volume":"17","author":"S Lahnwong","year":"2018","unstructured":"Lahnwong, S., Chattipakorn, S. C., & Chattipakorn, N. (2018). Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. Cardiovascular Diabetology, 17, 1\u20137. https:\/\/doi.org\/10.1186\/s12933-018-0745-5","journal-title":"Cardiovascular Diabetology"},{"key":"9784_CR79","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/JOE-17-0457","volume":"236","author":"P Tanajak","year":"2018","unstructured":"Tanajak, P., Sa-Nguanmoo, P., Sivasinprasasn, S., Thummasorn, S., Siri-Angkul, N., Chattipakorn, S. C., & Chattipakorn, N. (2018). Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. Journal of Endocrinology, 236, 69\u201384. https:\/\/doi.org\/10.1530\/JOE-17-0457","journal-title":"Journal of Endocrinology"},{"key":"9784_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0474-6","author":"E Lucas","year":"2016","unstructured":"Lucas, E., Vila-Bedmar, R., Arcones, A. C., Cruces-Sande, M., Cachofeiro, V., Mayor, F., & Murga, C. (2016). Obesity-induced cardiac lipid accumulation in adult mice is modulated by G protein-coupled receptor kinase 2 levels. Cardiovascular Diabetology. https:\/\/doi.org\/10.1186\/s12933-016-0474-6","journal-title":"Cardiovascular Diabetology"},{"key":"9784_CR81","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00246-011-9889-8","volume":"32","author":"JG Duncan","year":"2011","unstructured":"Duncan, J. G. (2011). Peroxisome proliferator-activated receptor-alpha (PPAR\u03b1) and PPAR gamma coactivator-1alpha (PGC-1\u03b1) regulation of cardiac metabolism in diabetes. Pediatric Cardiology, 32, 323\u2013328. https:\/\/doi.org\/10.1007\/s00246-011-9889-8","journal-title":"Pediatric Cardiology"},{"key":"9784_CR82","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2147\/TCRM.S275076","volume":"17","author":"M Gupta","year":"2021","unstructured":"Gupta, M., Rao, S., Manek, G., Fonarow, G. C., & Ghosh, R. K. (2021). The role of dapagliflozin in the management of heart failure: An update on the emerging evidence. Therapeutics and Clinical Risk Management, 17, 823\u2013830. https:\/\/doi.org\/10.2147\/TCRM.S275076","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"9784_CR83","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohl\u00e1vek, J., B\u00f6hm, M., Chiang, C. E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Duk\u00e1t, A., Ge, J., Howlett, J., Katova, T., Kitakaze, M., Ljungman, C. E. A., et al. (2020). Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA, 323, 1353\u20131368. https:\/\/doi.org\/10.1001\/jama.2020.1906","journal-title":"JAMA"},{"key":"9784_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcdhc.2021.703937","volume":"2","author":"Z Miaobo","year":"2021","unstructured":"Miaobo, Z., Changmei, L., Xin, D., & Huipu, X. (2021). The effects of Dapagliflozin in patients with heart failure complicated with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. Front. Clin. Diabetes Healthc, 2, 1\u201310. https:\/\/doi.org\/10.3389\/fcdhc.2021.703937","journal-title":"Front. Clin. Diabetes Healthc"},{"key":"9784_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9388562","volume":"2021","author":"L Xue","year":"2021","unstructured":"Xue, L., Yuan, X., Zhang, S., & Zhao, X. (2021). Investigating the effects of dapagliflozin on cardiac function, inflammatory response and cardiovascular outcome in patients with STEMI complicated with T2DM after PCI. Evid Based Complement Alternat Med, 2021, 1\u20136. https:\/\/doi.org\/10.1155\/2021\/9388562","journal-title":"Evid Based Complement Alternat Med"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-023-09784-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-023-09784-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-023-09784-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T09:24:07Z","timestamp":1677144247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-023-09784-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["9784"],"URL":"https:\/\/doi.org\/10.1007\/s12012-023-09784-8","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"20 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}